Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series
Immunotherapy with immune checkpoint inhibitors (ICIs) have been reported to induce de novo or exacerbate pre-existing Myasthenia Gravis (MG). We present a single center case series of patients who developed an immune-related myasthenia gravis (irMG) related with ICIs. We performed a retrospective c...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/1/130 |
| _version_ | 1797625474628714496 |
|---|---|
| author | Carla Marco Marta Simó Montse Alemany Carlos Casasnovas Raúl Domínguez Noelia Vilariño Mariona Calvo Juan Martín-Liberal Jesús Brenes Joan Sabater-Riera Jordi Bruna Roser Velasco |
| author_facet | Carla Marco Marta Simó Montse Alemany Carlos Casasnovas Raúl Domínguez Noelia Vilariño Mariona Calvo Juan Martín-Liberal Jesús Brenes Joan Sabater-Riera Jordi Bruna Roser Velasco |
| author_sort | Carla Marco |
| collection | DOAJ |
| description | Immunotherapy with immune checkpoint inhibitors (ICIs) have been reported to induce de novo or exacerbate pre-existing Myasthenia Gravis (MG). We present a single center case series of patients who developed an immune-related myasthenia gravis (irMG) related with ICIs. We performed a retrospective chart review of the electronic medical records between 1 September 2017 and 2022. We report the clinical features, presentation forms, diagnostic workflows, general management and outcomes of six patients who received ICIs for different solid organ malignancies and developed an irMG frequently overlapping with immune-related myocarditis and/or myositis. The aim of the article is to describe the clinical features, treatment and outcomes of this challenging and potentially life-threating syndrome, comparing our data with those described in the literature. Differences between irMG and classic MG are highlighted. |
| first_indexed | 2024-03-11T09:57:00Z |
| format | Article |
| id | doaj.art-8d243d0d5f6142a098fe27cda47894f9 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T09:57:00Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-8d243d0d5f6142a098fe27cda47894f92023-11-16T15:41:49ZengMDPI AGJournal of Clinical Medicine2077-03832022-12-0112113010.3390/jcm12010130Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case SeriesCarla Marco0Marta Simó1Montse Alemany2Carlos Casasnovas3Raúl Domínguez4Noelia Vilariño5Mariona Calvo6Juan Martín-Liberal7Jesús Brenes8Joan Sabater-Riera9Jordi Bruna10Roser Velasco11Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), 08908 L’Hospitalet de Llobregat, SpainNeuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), 08908 L’Hospitalet de Llobregat, SpainNeuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), 08908 L’Hospitalet de Llobregat, SpainNeuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge, 08907 L’Hospitalet de Llobregat, SpainNeuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge, 08907 L’Hospitalet de Llobregat, SpainNeuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), 08908 L’Hospitalet de Llobregat, SpainDepartment of Oncology, Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), 08908 L’Hospitalet de Llobregat, SpainDepartment of Oncology, Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), 08908 L’Hospitalet de Llobregat, SpainDepartment of Oncology, Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), 08908 L’Hospitalet de Llobregat, SpainCritical Care Department, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Universitari de Bellvitge, 08908 L’Hospitalet de Llobregat, SpainNeuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), 08908 L’Hospitalet de Llobregat, SpainNeuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), 08908 L’Hospitalet de Llobregat, SpainImmunotherapy with immune checkpoint inhibitors (ICIs) have been reported to induce de novo or exacerbate pre-existing Myasthenia Gravis (MG). We present a single center case series of patients who developed an immune-related myasthenia gravis (irMG) related with ICIs. We performed a retrospective chart review of the electronic medical records between 1 September 2017 and 2022. We report the clinical features, presentation forms, diagnostic workflows, general management and outcomes of six patients who received ICIs for different solid organ malignancies and developed an irMG frequently overlapping with immune-related myocarditis and/or myositis. The aim of the article is to describe the clinical features, treatment and outcomes of this challenging and potentially life-threating syndrome, comparing our data with those described in the literature. Differences between irMG and classic MG are highlighted.https://www.mdpi.com/2077-0383/12/1/130myasthenia gravisimmune checkpoint inhibitorsimmune-related adverse eventsneurotoxicityneuro-oncology |
| spellingShingle | Carla Marco Marta Simó Montse Alemany Carlos Casasnovas Raúl Domínguez Noelia Vilariño Mariona Calvo Juan Martín-Liberal Jesús Brenes Joan Sabater-Riera Jordi Bruna Roser Velasco Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series Journal of Clinical Medicine myasthenia gravis immune checkpoint inhibitors immune-related adverse events neurotoxicity neuro-oncology |
| title | Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series |
| title_full | Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series |
| title_fullStr | Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series |
| title_full_unstemmed | Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series |
| title_short | Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series |
| title_sort | myasthenia gravis induced by immune checkpoint inhibitors an emerging neurotoxicity in neuro oncology practice case series |
| topic | myasthenia gravis immune checkpoint inhibitors immune-related adverse events neurotoxicity neuro-oncology |
| url | https://www.mdpi.com/2077-0383/12/1/130 |
| work_keys_str_mv | AT carlamarco myastheniagravisinducedbyimmunecheckpointinhibitorsanemergingneurotoxicityinneurooncologypracticecaseseries AT martasimo myastheniagravisinducedbyimmunecheckpointinhibitorsanemergingneurotoxicityinneurooncologypracticecaseseries AT montsealemany myastheniagravisinducedbyimmunecheckpointinhibitorsanemergingneurotoxicityinneurooncologypracticecaseseries AT carloscasasnovas myastheniagravisinducedbyimmunecheckpointinhibitorsanemergingneurotoxicityinneurooncologypracticecaseseries AT rauldominguez myastheniagravisinducedbyimmunecheckpointinhibitorsanemergingneurotoxicityinneurooncologypracticecaseseries AT noeliavilarino myastheniagravisinducedbyimmunecheckpointinhibitorsanemergingneurotoxicityinneurooncologypracticecaseseries AT marionacalvo myastheniagravisinducedbyimmunecheckpointinhibitorsanemergingneurotoxicityinneurooncologypracticecaseseries AT juanmartinliberal myastheniagravisinducedbyimmunecheckpointinhibitorsanemergingneurotoxicityinneurooncologypracticecaseseries AT jesusbrenes myastheniagravisinducedbyimmunecheckpointinhibitorsanemergingneurotoxicityinneurooncologypracticecaseseries AT joansabaterriera myastheniagravisinducedbyimmunecheckpointinhibitorsanemergingneurotoxicityinneurooncologypracticecaseseries AT jordibruna myastheniagravisinducedbyimmunecheckpointinhibitorsanemergingneurotoxicityinneurooncologypracticecaseseries AT roservelasco myastheniagravisinducedbyimmunecheckpointinhibitorsanemergingneurotoxicityinneurooncologypracticecaseseries |